Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Arrowhead Pharmaceuticals Inc. (ARWR) Reports Q1 Loss of $0.20
February 4, 2021 4:40 PM ESTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($0.20), versus ($0.03) reported last year. Revenue for the quarter came in at $21.3 million, versus $29.46 million reported last year.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
... More